2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 818

Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 734

Correlation of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis with Serum Biomarkers of Fibrogenesis in an Observational Cohort

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 252

Correlations between Clinical and Ultrasound Scores of Peripheral Enthesitis and Disease Activity Scores in a Cohort of Spondyloarthritis

Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 278

Corticosteroid Use, Biologic Therapy Switching, Smoking and Renal Failure Are Associated with Serious Infections in Rheumatoid Arthritis Patients Treated with Biologics: Data from Two Latin-American Registries

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 408

CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 216

Creation of the First Massive Open Online Course for Patients with Rheumatoid Arthritis

ARHP Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 38

Cytokine Production By CpG-Activated B Cells Require Glutaminolysis to Drive mTOR Activation, Aerobic Glycolysis and Mitochondrial Respiration

B Cell Biology and Targets in Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 710

D-Dimer As an Early Marker in Patients with Lupus Mesenteric Vasculitis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 784

Damage and Predictors of Damage in Takayasu’s Arteritis

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 553

Decreased Circulating CXCR3+CCR9+ Th Cells Coincides with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Sjögren’s Syndrome Patients Which Synergistically Facilitate Th Cell Migration

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 223

Decreased Medication Adherence Is a Major Cause for Increased Risk of Hospitalizations Among High Risk Lupus Patients

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 541

Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 391

Defective Glucose and Lipid Metabolism in Rheumatoid Arthritis Is Determined By Chronic Inflammation in Metabolic Tissues

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 121

Depression As a Risk Factor for the Development of Rheumatoid Arthritis: A Population-Based Cohort Study

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 162

Depression Versus Frustration

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].